Today, I review, link to, and excerpt from CoreIM’s Lp(a) and ASCVD Risk: 5 Pearls Segment.

All that follows is from the above resource.

5 Pearls Episodes By Series Episodes By Topic 🏡 Primary Care 🫀 Cardiology

Lp(a) and ASCVD Risk: 5 Pearls Segment

Posted: April 2, 2025
By: Dr. Ian Kelly, Dr. Steven Nissen, Dr. Ariane Fraiche, Dr. Greg Katz and Dr. Shreya P. Trivedi
Graphic: Dr. Jesse Powell
Audio: Jerome C. Reyes
Peer Review: Dr. Evan Harmon, Dr. Thomas Dayspring

Audio Player

Podcast: Play in new window | Download

Time Stamps CME-MOC Show Notes Transcript Behind the Scenes Interviews References

Time Stamps

• 02:17 Pearl 1: What makes Lp(a) unique? How does it raise ASCVD risk?
• 10:32 Pearl 2: Who should be tested for Lp(a)? When and why?
• 16:54 Pearl 3: Understanding and interpreting Lp(a) levels
• 24:04 Pearl 4: How does an elevated Lp(a) affect management?
• 37:05 Pearl 5: The role of aspirin and PCSK9 inhibitors in Lp(a)

CME-MOC

• Get CME-MOC credit with ACP!

Sponsor: Freed is an AI scribe that listens and writes your note in < 30 seconds. Freed learns your style over time and is HIPAA compliant!

Use the code “CORE50” to get 50% off your first month with Freed

149 views Mar 30, 2025 #cardiology #residency #heartattack

Key Points:

• Elevated Lp (a) is common and strongly associated with atherosclerotic vascular disease and aortic stenosis.
• Lp (a) levels are largely genetically determined.
• Lp (a) elevation in one family member may indicate that others should be tested.
• People with highly elevated Lp (a) benefit from intensified measures to reduce CV risk (i.e. lifestyle modification, statin, and aspirin therapy).

To learn more about lipoprotein (a) testing and implications, check out the 5-Pearls episode at our website! You can also check out more videos like this one by subscribing to our YouTube Channel. Thanks for watching! https://www.coreimpodcast.com/ Guest Expert: Dr. Steven Nissen, Cardiologist and renowned researcher Original Interview by: Dr. Ian Kelly Video by: Dr. Ananya Gorrai & Dr. Alice Kennedy #cardiology, #ASCVD, #lipids, #prevention, #primarycare, #internalmedicine, #medicaleducation, #residency, #CoreIM, #IMcore, #heartattack

Transcript

Follow along using the transcript on YouTube

505 views Mar 30, 2025 #cardiology #residency #medicaleducation

Key Points:

• New strategies to durably reduce Lp(a) have great promise for loweing risk of MACE.
• Small interfering DNA or RNA particles are being designed to block lipoprotein a particle formation in hepatocytes.
• CRISPR technology may also be capable of knocking out the Lp (a) gene.
• These therapies have the potential to decrease Lp (a) and reduct CV risk over the longterm.

To learn more about lipoprotein (a) testing and implications, check out the 5-Pearls episode at our website! You can also check out more videos like this one by subscribing to our YouTube Channel. Thanks for watching! https://www.coreimpodcast.com/ Guest Expert: Dr. Steven Nissen, cardiologist Original Interview by: Dr. Ian Kelly Video by: Dr. Ananya Gorrai & Dr. Alice Kennedy #cardiology, #ASCVD, #lipids, #prevention, #primarycare, #internalmedicine, #medicaleducation, #residency, #CoreIM, #IMcore

Follow along using the transcript on YouTube.